Canine Gut Microbiome Biomarkers for Non-Invasive IBD Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing inflammatory bowel disease (IBD) in dogs are invasive and require veterinary pathologists, necessitating a non-invasive and more effective diagnostic approach.
Innovation Solution
A probiotic composition comprising specific bacterial species and a method for identifying IBD by measuring bacterial levels in fecal samples, along with a treatment approach to modulate gut bacterial populations to manage IBD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If invasive tissue biopsies are used for IBD diagnosis, then diagnostic accuracy is improved, but patient comfort and procedural complexity worsen
Solution Approach 1:
The patent extracts the diagnostic function from invasive tissue biopsy procedures and relocates it to non-invasive fecal sample analysis. By measuring bacterial species levels (such as Clostridium hylemonae, Ruminococcus gnavus, and Escherichia coli) in feces, the diagnostic capability is preserved while eliminating the need for surgical procedures and pathologist involvement.
Solution Approach 2:
The patent introduces fecal bacterial composition as an intermediary marker that reflects the underlying intestinal inflammation. Instead of directly examining intestinal tissue, the method uses the microbial community in feces as a surrogate indicator of IBD pathology, enabling indirect but accurate diagnosis through non-invasive sampling.
2Measurement precision
If invasive tissue biopsies are used for IBD diagnosis, then diagnostic accuracy is improved, but cost and resource requirements worsen
Solution Approach 1:
The patent extracts the diagnostic function from complex tissue biopsy procedures requiring veterinary pathologists and relocates it to simpler fecal sample analysis. The diagnostic capability is preserved through measurement of bacterial species levels using molecular techniques, eliminating the need for specialized pathologist expertise and expensive surgical facilities.
Solution Approach 2:
The patent replaces the mechanical and manual tissue biopsy process with molecular analysis of fecal samples. Instead of surgically obtaining and physically examining tissue, the method uses DNA-based detection of bacterial species composition, substituting a complex mechanical procedure with a more streamlined molecular assay.
3Reliability
If probiotic composition is administered to modulate gut bacteria, then IBD symptoms are improved, but treatment complexity increases
Solution Approach 1:
The patent changes the microbial composition parameter of the gut by administering specific probiotic formulations. By introducing beneficial bacterial species and modulating the microbiome structure, the treatment addresses the root cause of IBD rather than merely suppressing symptoms, thereby improving long-term effectiveness through a targeted biological parameter modification.
Data Source
AI summary
Provided herein are methods for detecting inflammatory bowel disease (IBD) or risk of IBD in a canine based on the canine's gut microbiome. Also provided are methods for treating or preventing IBD in canines. Finally provided are probiotic compositions that are used in the methods of the present disclosure.